Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
ESMO Congress 2026 · Barcelona, Spain
200 shown of 2,402 total abstracts
  1. Abstract 19502026-09-03 · 13:15 CT · Hall B1
    Quality of life outcomes with Verzenio in patients with HR+ breast cancer
    S. Peters, J. Brahmer, F. Andre, et al. · Princess Margaret Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  2. Abstract 16132026-09-05 · 13:30 CT · S406
    Quality of life outcomes with Lynparza in patients with HR+ breast cancer
    J. Cortes, R. Herbst, H. Rugo · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  3. Abstract 90532026-09-04 · 13:30 CT · E450
    FLAURA-858: Tagrisso (osimertinib) 1L in NSCLC
    P. Schmid, M. Reck, A. Spira, et al. · Cleveland Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  4. Abstract 13972026-09-04 · 14:30 CT · Arie Crown Theater
    Real-world effectiveness of Kisqali vs standard of care in HR+ breast cancer
    M.C. Garassino, H. Borghaei, M. Reck, et al. · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  5. Abstract 41962026-09-02 · 13:15 CT · Hall B1
    Real-world effectiveness of Opdivo vs standard of care in HCC
    J. Brahmer, M.C. Garassino, C. Saura · Karolinska Institute
    Poster SessionGastrointestinal Cancer📄🖼️
  6. Abstract 44992026-09-05 · 14:00 CT · S406
    Long-term follow-up of Imfinzi neoadjuvant for biliary tract: PACIFIC-605
    N. Rizvi, M.C. Garassino, L. Paz-Ares, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionGastrointestinal Cancer📄🖼️
  7. Abstract 14152026-09-03 · 14:00 CT · Arie Crown Theater
    Quality of life outcomes with Kisqali in patients with HR+ breast cancer
    J. Brahmer, M. Krop, L. Paz-Ares, et al. · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  8. Abstract 14302026-09-05 · 15:45 CT · S406
    MONALEESA-489: Kisqali (ribociclib) neoadjuvant in HR+ breast cancer
    A. Spira, C. Saura, M. Reck, et al. · Peter MacCallum Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  9. Abstract 13222026-09-05 · 19:15 CT · Hall B1
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-20
    H. Borghaei, T. Mok, H. Rugo, et al. · Princess Margaret Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  10. Abstract 93922026-09-04 · 20:15 CT · S406
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-312
    M. Krop, H. Borghaei, C. Robert · Chinese University of Hong Kong
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  11. Abstract 40182026-09-02 · 19:15 CT · Arie Crown Theater
    EV-634: Padcev (enfortumab vedotin) 2L in urothelial carcinoma
    S. Peters, H. Rugo · Royal Marsden Hospital
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  12. Abstract 47782026-09-02 · 18:00 CT · Hall B1
    Quality of life outcomes with Padcev in patients with urothelial carcinoma
    A. Spira, R. Herbst · Peter MacCallum Cancer Centre
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  13. Abstract 14652026-09-02 · 19:45 CT · E450
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-236 study)
    S. Antonia, H. Borghaei · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  14. Abstract 18162026-09-04 · 18:15 CT · S100A
    Long-term follow-up of Ibrance 2L for HR+ breast cancer: PALOMA-111
    P. Schmid, A. Spira, J. Brahmer · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  15. Abstract 92842026-09-04 · 21:30 CT · E450
    Quality of life outcomes with Enhertu in patients with NSCLC
    M. Krop, M. Reck · Mayo Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  16. Abstract 16592026-09-05 · 21:30 CT · Hall B1
    Long-term follow-up of Enhertu adjuvant for HR+ breast cancer: DESTINY-Breast-876
    E. Winer, H. Borghaei, H. Rugo, et al. · Peter MacCallum Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  17. Abstract 43282026-09-01 · 14:00 CT · S100A
    Quality of life outcomes with Imfinzi in patients with biliary tract
    S. Peters, A. Spira, C. Robert · National Cancer Center Japan
    Poster SessionGastrointestinal Cancer📄🖼️
  18. Abstract 95782026-09-01 · 16:15 CT · S406
    IMpower-446: Tecentriq (atezolizumab) adjuvant in NSCLC
    R. Herbst, H. Rugo · Stanford Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  19. Abstract 56022026-09-01 · 15:30 CT · S406
    OlympiA-195: Lynparza (olaparib) 2L in prostate
    C. Saura, M.C. Garassino, L. Paz-Ares, et al. · National Cancer Center Japan
    Poster SessionGenitourinary Cancer—Prostate📄🖼️
  20. Abstract 66862026-09-01 · 15:30 CT · S406
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-819
    C. Robert, M. Reck, H. Borghaei, et al. · Chinese University of Hong Kong
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  21. Abstract 91892026-09-05 · 20:00 CT · S406
    Imfinzi plus chemotherapy in previously untreated NSCLC: updated analysis from PACIFIC-250
    H. Borghaei, M. Reck, R. Herbst, et al. · Princess Margaret Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  22. Abstract 93892026-09-03 · 15:00 CT · Hall B1
    Real-world effectiveness of Tagrisso vs standard of care in NSCLC
    M. Reck, S. Tolaney · Johns Hopkins Kimmel Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  23. Abstract 12062026-09-05 · 20:15 CT · Hall B1
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-470
    L. Paz-Ares, A. Spira · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
  24. Abstract 48122026-09-02 · 18:00 CT · S100A
    Quality of life outcomes with Enhertu in patients with gastric
    C. Robert, J. Brahmer · Vall d'Hebron Institute of Oncology
    Poster SessionGastrointestinal Cancer📄🖼️
  25. Abstract 94832026-09-03 · 18:00 CT · Hall B1
    Real-world effectiveness of Enhertu vs standard of care in NSCLC
    T. Mok, S. Antonia, P. Schmid, et al. · Dana-Farber Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  26. Abstract 96742026-09-01 · 13:15 CT · Arie Crown Theater
    Quality of life outcomes with Keytruda in patients with SCLC
    H. Borghaei, T. Mok, J. Cortes · University of Chicago
    Poster SessionLung Cancer—Small Cell📄🖼️
  27. Abstract 18972026-09-05 · 20:30 CT · S100A
    MONARCH-45: Verzenio (abemaciclib) 3L+ in HR+ breast cancer
    L. Paz-Ares, J. Cortes · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  28. Abstract 53282026-09-05 · 13:30 CT · Hall B1
    OlympiA-751: Lynparza (olaparib) adjuvant in prostate
    F. Andre, S. Antonia · Massachusetts General Hospital
    Poster SessionGenitourinary Cancer—Prostate📄🖼️
  29. Abstract 97612026-09-01 · 19:00 CT · S406
    FLAURA-16: Tagrisso (osimertinib) adjuvant in NSCLC
    J. Brahmer, M. Krop, G. Curigliano, et al. · Peter MacCallum Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  30. Abstract 94242026-09-01 · 14:00 CT · Arie Crown Theater
    Long-term follow-up of Imfinzi maintenance for SCLC: PACIFIC-59
    F. Andre, H. Rugo, A. Spira, et al. · Dana-Farber Cancer Institute
    Poster SessionLung Cancer—Small Cell📄🖼️
  31. Abstract 99772026-09-01 · 13:30 CT · Arie Crown Theater
    Long-term follow-up of Tecentriq maintenance for NSCLC: IMpower-299
    F. Andre, M. Reck, H. Borghaei, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  32. Abstract 99992026-09-03 · 18:15 CT · S406
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-652 study)
    H. Rugo, S. Tolaney · MD Anderson Cancer Center
    Poster SessionMelanoma📄🖼️
  33. Abstract 46722026-09-03 · 18:45 CT · S406
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-537
    T. Mok, H. Rugo, S. Antonia, et al. · Chinese University of Hong Kong
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  34. Abstract 40702026-09-01 · 19:45 CT · Arie Crown Theater
    EV-183: Padcev (enfortumab vedotin) neoadjuvant in urothelial carcinoma
    T. Mok, M. Krop, F. Andre, et al. · Mayo Clinic
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  35. Abstract 10832026-09-04 · 13:45 CT · Arie Crown Theater
    Long-term follow-up of Kisqali 1L for HR+ breast cancer: MONALEESA-550
    M.C. Garassino, E. Winer · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
  36. Abstract 95602026-09-05 · 19:45 CT · S100A
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-143 study)
    H. Borghaei, E. Winer, T. Mok · Chinese University of Hong Kong
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  37. Abstract 12362026-09-04 · 18:45 CT · S100A
    IMpower-742: Tecentriq (atezolizumab) 3L+ in TNBC
    J. Brahmer, F. Andre, A. Spira · MD Anderson Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  38. Abstract 19112026-09-05 · 13:00 CT · S100A
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-275
    E. Winer, H. Borghaei, H. Rugo · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  39. Abstract 10642026-09-02 · 15:15 CT · S100A
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-657
    P. Schmid, C. Saura, S. Modi, et al. · Princess Margaret Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  40. Abstract 46692026-09-04 · 20:00 CT · S100A
    Biomarker subgroup analysis of Padcev in urothelial carcinoma (the EV-387 study)
    R. Herbst, S. Modi, S. Tolaney, et al. · Princess Margaret Cancer Centre
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  41. Abstract 97242026-09-03 · 21:15 CT · S406
    Quality of life outcomes with Opdivo in patients with NSCLC
    M. Reck, H. Borghaei, P. Schmid, et al. · Princess Margaret Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  42. Abstract 45832026-09-03 · 13:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Imfinzi in biliary tract (the PACIFIC-935 study)
    R. Herbst, S. Antonia, G. Curigliano, et al. · Massachusetts General Hospital
    Poster SessionGastrointestinal Cancer📄🖼️
  43. Abstract 10892026-09-04 · 21:00 CT · Arie Crown Theater
    Quality of life outcomes with Ibrance in patients with HR+ breast cancer
    N. Rizvi, H. Rugo, S. Modi, et al. · National Cancer Center Japan
    Poster SessionBreast Cancer—Metastatic📄🖼️
  44. Abstract 58792026-09-04 · 21:45 CT · S100A
    Long-term follow-up of Lynparza 3L+ for prostate: OlympiA-823
    J. Brahmer, M. Krop, R. Herbst · Chinese University of Hong Kong
    Poster SessionGenitourinary Cancer—Prostate📄🖼️
  45. Abstract 55612026-09-04 · 21:30 CT · Arie Crown Theater
    OlympiA-972: Lynparza (olaparib) neoadjuvant in prostate
    S. Tolaney, G. Curigliano, F. Andre, et al. · Royal Marsden Hospital
    Poster SessionGenitourinary Cancer—Prostate📄🖼️
  46. Abstract 60102026-09-03 · 19:30 CT · Arie Crown Theater
    Quality of life outcomes with Opdivo in patients with RCC
    S. Peters, R. Herbst, F. Andre · Princess Margaret Cancer Centre
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  47. Abstract 12022026-09-01 · 19:00 CT · S406
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-40
    J. Cortes, C. Robert, T. Mok, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  48. Abstract 18232026-09-02 · 20:30 CT · Hall B1
    Quality of life outcomes with Tecentriq in patients with TNBC
    M. Reck, J. Brahmer, S. Modi, et al. · National Cancer Center Japan
    Poster SessionBreast Cancer—Metastatic📄🖼️
  49. Abstract 95772026-09-04 · 16:30 CT · S406
    Keytruda plus chemotherapy in previously untreated metastatic melanoma: updated analysis from KEYNOTE-111
    E. Winer, M. Reck, M. Krop, et al. · Dana-Farber Cancer Institute
    Poster SessionMelanoma📄🖼️
  50. Abstract 40212026-09-04 · 21:15 CT · Arie Crown Theater
    Long-term follow-up of Trodelvy neoadjuvant for urothelial carcinoma: ASCENT-640
    J. Brahmer, E. Winer, N. Rizvi · Stanford Cancer Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  51. Abstract 99852026-09-01 · 21:00 CT · S406
    Imfinzi plus chemotherapy in previously untreated NSCLC: updated analysis from PACIFIC-848
    C. Robert, C. Saura, T. Mok, et al. · MD Anderson Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  52. Abstract 17592026-09-03 · 13:45 CT · Hall B1
    Long-term follow-up of Kisqali maintenance for HR+ breast cancer: MONALEESA-764
    S. Peters, A. Spira, N. Rizvi, et al. · Peter MacCallum Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  53. Abstract 48982026-09-04 · 18:15 CT · Arie Crown Theater
    ASCENT-880: Trodelvy (sacituzumab govitecan) 3L+ in urothelial carcinoma
    H. Rugo, F. Andre, T. Mok, et al. · MD Anderson Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  54. Abstract 12022026-09-05 · 15:30 CT · S100A
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-62
    S. Antonia, S. Tolaney, R. Herbst · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  55. Abstract 92402026-09-02 · 13:00 CT · S406
    KEYNOTE-686: Keytruda (pembrolizumab) 1L in SCLC
    C. Robert, G. Curigliano, P. Schmid · Stanford Cancer Institute
    Poster SessionLung Cancer—Small Cell📄🖼️
  56. Abstract 10592026-09-01 · 18:30 CT · S406
    Quality of life outcomes with Trodelvy in patients with TNBC
    M. Krop, G. Curigliano, R. Herbst, et al. · National Cancer Center Japan
    Poster SessionBreast Cancer—Metastatic📄🖼️
  57. Abstract 95642026-09-01 · 13:30 CT · S100A
    Opdivo plus chemotherapy in previously untreated NSCLC: updated analysis from CheckMate-600
    C. Robert, R. Herbst · National Cancer Center Japan
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  58. Abstract 11522026-09-02 · 21:30 CT · S406
    MONARCH-387: Verzenio (abemaciclib) neoadjuvant in HR+ breast cancer
    T. Mok, S. Peters, J. Cortes, et al. · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  59. Abstract 94832026-09-02 · 19:30 CT · S406
    Biomarker subgroup analysis of Keytruda in SCLC (the KEYNOTE-278 study)
    P. Schmid, F. Andre · Johns Hopkins Kimmel Cancer Center
    Poster SessionLung Cancer—Small Cell📄🖼️
  60. Abstract 44782026-09-02 · 20:45 CT · S100A
    Long-term follow-up of Padcev 1L for urothelial carcinoma: EV-729
    P. Schmid, R. Herbst, E. Winer, et al. · National Cancer Center Japan
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  61. Abstract 12302026-09-04 · 21:45 CT · S100A
    MONALEESA-675: Kisqali (ribociclib) 3L+ in HR+ breast cancer
    G. Curigliano, F. Andre, N. Rizvi, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionBreast Cancer—Metastatic📄🖼️
  62. Abstract 49312026-09-03 · 19:45 CT · S406
    CheckMate-855: Opdivo (nivolumab) 2L in HCC
    G. Curigliano, M. Reck · Mayo Clinic
    Poster SessionGastrointestinal Cancer📄🖼️
  63. Abstract 99542026-09-03 · 14:15 CT · S406
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-620 study)
    T. Mok, M. Reck · Vall d'Hebron Institute of Oncology
    Poster SessionMelanoma📄🖼️
  64. Abstract 48802026-09-03 · 15:00 CT · Arie Crown Theater
    Long-term follow-up of Padcev adjuvant for urothelial carcinoma: EV-131
    M.C. Garassino, G. Curigliano, P. Schmid, et al. · Stanford Cancer Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  65. Abstract 10742026-09-05 · 20:30 CT · S406
    MONALEESA-532: Kisqali (ribociclib) adjuvant in HR+ breast cancer
    R. Herbst, F. Andre, J. Cortes, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  66. Abstract 91172026-09-02 · 21:30 CT · S100A
    Keytruda plus chemotherapy in previously untreated NSCLC: updated analysis from KEYNOTE-781
    S. Antonia, S. Tolaney, C. Saura, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  67. Abstract 96602026-09-04 · 19:45 CT · Hall B1
    Biomarker subgroup analysis of Imfinzi in NSCLC (the PACIFIC-489 study)
    J. Brahmer, A. Spira, T. Mok, et al. · Cleveland Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  68. Abstract 62422026-09-05 · 19:30 CT · E450
    Long-term follow-up of Keytruda 1L for RCC: KEYNOTE-182
    R. Herbst, T. Mok, M. Reck · Cleveland Clinic
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  69. Abstract 16042026-09-03 · 18:30 CT · E450
    Real-world effectiveness of Verzenio vs standard of care in HR+ breast cancer
    C. Saura, J. Brahmer, M.C. Garassino, et al. · MD Anderson Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  70. Abstract 98712026-09-05 · 18:15 CT · S100A
    Quality of life outcomes with Tecentriq in patients with NSCLC
    R. Herbst, M. Krop, T. Mok, et al. · Dana-Farber Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  71. Abstract 42222026-09-01 · 19:15 CT · S406
    Biomarker subgroup analysis of Padcev in urothelial carcinoma (the EV-251 study)
    N. Rizvi, R. Herbst, C. Robert, et al. · Princess Margaret Cancer Centre
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  72. Abstract 44632026-09-01 · 13:45 CT · S406
    IMpower-493: Tecentriq (atezolizumab) maintenance in HCC
    J. Brahmer, C. Robert, R. Herbst, et al. · Peter MacCallum Cancer Centre
    Poster SessionGastrointestinal Cancer📄🖼️
  73. Abstract 92022026-09-05 · 14:30 CT · E450
    Long-term follow-up of Keytruda 1L for SCLC: KEYNOTE-642
    E. Winer, S. Antonia, M. Reck · Dana-Farber Cancer Institute
    Poster SessionLung Cancer—Small Cell📄🖼️
  74. Abstract 17992026-09-05 · 15:00 CT · Hall B1
    Long-term follow-up of Enhertu adjuvant for HR+ breast cancer: DESTINY-Breast-724
    E. Winer, J. Cortes, L. Paz-Ares · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
  75. Abstract 16732026-09-05 · 21:00 CT · Arie Crown Theater
    MONALEESA-44: Kisqali (ribociclib) maintenance in HR+ breast cancer
    S. Antonia, L. Paz-Ares, P. Schmid · Stanford Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  76. Abstract 57152026-09-01 · 13:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Lynparza in prostate (the OlympiA-831 study)
    F. Andre, R. Herbst · National Cancer Center Japan
    Poster SessionGenitourinary Cancer—Prostate📄🖼️
  77. Abstract 90862026-09-04 · 18:30 CT · Arie Crown Theater
    Real-world effectiveness of Imfinzi vs standard of care in SCLC
    G. Curigliano, A. Spira, C. Robert, et al. · MD Anderson Cancer Center
    Poster SessionLung Cancer—Small Cell📄🖼️
  78. Abstract 13082026-09-02 · 20:45 CT · S406
    IMpower-583: Tecentriq (atezolizumab) 2L in TNBC
    S. Tolaney, R. Herbst · Princess Margaret Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  79. Abstract 90852026-09-02 · 19:30 CT · S406
    FLAURA-686: Tagrisso (osimertinib) adjuvant in NSCLC
    R. Herbst, C. Saura · MD Anderson Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  80. Abstract 47372026-09-01 · 18:45 CT · Arie Crown Theater
    PACIFIC-698: Imfinzi (durvalumab) neoadjuvant in biliary tract
    L. Paz-Ares, S. Modi, T. Mok, et al. · Karolinska Institute
    Poster SessionGastrointestinal Cancer📄🖼️
  81. Abstract 16262026-09-04 · 20:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-51 study)
    C. Robert, H. Rugo, S. Tolaney · MD Anderson Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  82. Abstract 41992026-09-03 · 21:45 CT · S406
    Real-world effectiveness of Enhertu vs standard of care in gastric
    F. Andre, E. Winer, M. Reck · Stanford Cancer Institute
    Poster SessionGastrointestinal Cancer📄🖼️
  83. Abstract 15562026-09-03 · 19:00 CT · Hall B1
    Real-world effectiveness of Trodelvy vs standard of care in TNBC
    C. Saura, T. Mok, F. Andre, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  84. Abstract 14342026-09-04 · 21:30 CT · Arie Crown Theater
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-835
    C. Robert, P. Schmid, M. Krop, et al. · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  85. Abstract 92632026-09-04 · 14:30 CT · E450
    Biomarker subgroup analysis of Tecentriq in NSCLC (the IMpower-903 study)
    E. Winer, M.C. Garassino, C. Saura, et al. · Cleveland Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  86. Abstract 11192026-09-01 · 16:00 CT · Arie Crown Theater
    PALOMA-120: Ibrance (palbociclib) 2L in HR+ breast cancer
    T. Mok, L. Paz-Ares, S. Antonia, et al. · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  87. Abstract 41882026-09-05 · 15:15 CT · S100A
    Long-term follow-up of Trodelvy neoadjuvant for urothelial carcinoma: ASCENT-358
    E. Winer, T. Mok, M.C. Garassino, et al. · Princess Margaret Cancer Centre
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  88. Abstract 44072026-09-03 · 13:30 CT · Hall B1
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-733
    C. Saura, P. Schmid, A. Spira, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  89. Abstract 16292026-09-03 · 14:00 CT · Hall B1
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-102
    E. Winer, M. Reck, S. Antonia, et al. · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  90. Abstract 40042026-09-04 · 20:30 CT · Hall B1
    IMpower-966: Tecentriq (atezolizumab) adjuvant in HCC
    J. Brahmer, S. Modi, M.C. Garassino, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionGastrointestinal Cancer📄🖼️
  91. Abstract 97352026-09-05 · 19:00 CT · E450
    Long-term follow-up of Opdivo adjuvant for NSCLC: CheckMate-948
    M. Krop, L. Paz-Ares, C. Robert, et al. · Peter MacCallum Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  92. Abstract 59162026-09-05 · 19:15 CT · S406
    Lynparza plus chemotherapy in previously untreated ovarian: updated analysis from OlympiA-167
    S. Tolaney, G. Curigliano · MD Anderson Cancer Center
    Poster SessionGynecologic Cancer📄🖼️
  93. Abstract 11012026-09-02 · 13:45 CT · Hall B1
    Real-world effectiveness of Enhertu vs standard of care in HR+ breast cancer
    S. Antonia, M.C. Garassino · Peter MacCallum Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  94. Abstract 12722026-09-04 · 16:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-505 study)
    M.C. Garassino, L. Paz-Ares, F. Andre · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  95. Abstract 15752026-09-01 · 13:15 CT · E450
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-668
    E. Winer, C. Robert · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  96. Abstract 46162026-09-02 · 19:45 CT · Hall B1
    Opdivo plus chemotherapy in previously untreated HCC: updated analysis from CheckMate-339
    G. Curigliano, L. Paz-Ares, T. Mok, et al. · Peter MacCallum Cancer Centre
    Poster SessionGastrointestinal Cancer📄🖼️
  97. Abstract 10992026-09-02 · 15:45 CT · S406
    Biomarker subgroup analysis of Enhertu in HR+ breast cancer (the DESTINY-Breast-185 study)
    H. Rugo, S. Peters · National Cancer Center Japan
    Poster SessionBreast Cancer—Metastatic📄🖼️
  98. Abstract 93462026-09-01 · 21:45 CT · Hall B1
    FLAURA-117: Tagrisso (osimertinib) adjuvant in NSCLC
    S. Tolaney, P. Schmid, A. Spira · Dana-Farber Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  99. Abstract 92782026-09-01 · 20:30 CT · S406
    FLAURA-977: Tagrisso (osimertinib) 3L+ in NSCLC
    N. Rizvi, S. Modi, M.C. Garassino, et al. · Princess Margaret Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  100. Abstract 19202026-09-05 · 18:15 CT · Hall B1
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-332 study)
    J. Brahmer, S. Modi · Peter MacCallum Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  101. Abstract 12632026-09-01 · 20:00 CT · S406
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-463 study)
    S. Antonia, M. Krop, M. Reck · Princess Margaret Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  102. Abstract 100832026-09-05 · 15:15 CT · S406
    Quality of life outcomes with Opdivo in patients with metastatic melanoma
    J. Cortes, F. Andre, T. Mok, et al. · Institut Gustave Roussy
    Poster SessionMelanoma📄🖼️
  103. Abstract 14592026-09-01 · 18:30 CT · S100A
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-892 study)
    T. Mok, C. Robert, S. Peters, et al. · Chinese University of Hong Kong
    Poster SessionBreast Cancer—Metastatic📄🖼️
  104. Abstract 95682026-09-01 · 18:45 CT · Arie Crown Theater
    Long-term follow-up of Tagrisso neoadjuvant for NSCLC: FLAURA-589
    M. Reck, E. Winer · Peter MacCallum Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  105. Abstract 14532026-09-03 · 18:15 CT · S100A
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-491 study)
    S. Modi, J. Brahmer, M.C. Garassino, et al. · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  106. Abstract 11202026-09-02 · 13:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-478 study)
    P. Schmid, H. Borghaei, J. Cortes · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
  107. Abstract 46232026-09-05 · 18:45 CT · S100A
    Real-world effectiveness of Padcev vs standard of care in urothelial carcinoma
    S. Modi, P. Schmid, R. Herbst · Institut Gustave Roussy
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  108. Abstract 66682026-09-05 · 16:30 CT · S100A
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-558
    S. Peters, F. Andre, J. Cortes, et al. · Institut Gustave Roussy
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  109. Abstract 59102026-09-04 · 20:45 CT · S100A
    Real-world effectiveness of Lynparza vs standard of care in prostate
    A. Spira, T. Mok, S. Tolaney, et al. · Karolinska Institute
    Poster SessionGenitourinary Cancer—Prostate📄🖼️
  110. Abstract 48532026-09-01 · 14:45 CT · Arie Crown Theater
    Real-world effectiveness of Tecentriq vs standard of care in HCC
    S. Antonia, M. Reck, H. Rugo · Peter MacCallum Cancer Centre
    Poster SessionGastrointestinal Cancer📄🖼️
  111. Abstract 46502026-09-05 · 21:30 CT · Arie Crown Theater
    ASCENT-719: Trodelvy (sacituzumab govitecan) 1L in urothelial carcinoma
    E. Winer, S. Modi · MD Anderson Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  112. Abstract 17352026-09-01 · 16:45 CT · Hall B1
    DESTINY-Breast-99: Enhertu (trastuzumab deruxtecan) neoadjuvant in HR+ breast cancer
    J. Brahmer, S. Antonia, C. Robert, et al. · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  113. Abstract 61102026-09-05 · 21:45 CT · S100A
    Biomarker subgroup analysis of Lynparza in ovarian (the OlympiA-399 study)
    M.C. Garassino, S. Peters · Cleveland Clinic
    Poster SessionGynecologic Cancer📄🖼️
  114. Abstract 97052026-09-02 · 16:00 CT · E450
    Real-world effectiveness of Keytruda vs standard of care in metastatic melanoma
    E. Winer, S. Antonia, S. Peters, et al. · National Cancer Center Japan
    Poster SessionMelanoma📄🖼️
  115. Abstract 90642026-09-05 · 15:00 CT · S406
    Imfinzi plus chemotherapy in previously untreated NSCLC: updated analysis from PACIFIC-368
    R. Herbst, F. Andre, P. Schmid · Princess Margaret Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  116. Abstract 43492026-09-01 · 16:15 CT · Hall B1
    Biomarker subgroup analysis of Padcev in urothelial carcinoma (the EV-363 study)
    G. Curigliano, P. Schmid, H. Rugo, et al. · Royal Marsden Hospital
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  117. Abstract 90082026-09-01 · 16:30 CT · E450
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-266
    J. Brahmer, C. Robert · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  118. Abstract 102562026-09-05 · 16:15 CT · S100A
    CheckMate-889: Opdivo (nivolumab) adjuvant in metastatic melanoma
    H. Borghaei, T. Mok · Chinese University of Hong Kong
    Poster SessionMelanoma📄🖼️
  119. Abstract 13962026-09-02 · 15:45 CT · Hall B1
    MONARCH-427: Verzenio (abemaciclib) 3L+ in HR+ breast cancer
    M.C. Garassino, J. Brahmer, S. Peters · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  120. Abstract 68072026-09-04 · 15:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-538 study)
    T. Mok, C. Saura, R. Herbst, et al. · Massachusetts General Hospital
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  121. Abstract 42492026-09-05 · 16:00 CT · E450
    Biomarker subgroup analysis of Imfinzi in biliary tract (the PACIFIC-455 study)
    S. Modi, J. Brahmer, R. Herbst · MD Anderson Cancer Center
    Poster SessionGastrointestinal Cancer📄🖼️
  122. Abstract 54342026-09-01 · 14:15 CT · Hall B1
    Biomarker subgroup analysis of Lynparza in prostate (the OlympiA-975 study)
    M. Krop, S. Modi, R. Herbst, et al. · Institut Gustave Roussy
    Poster SessionGenitourinary Cancer—Prostate📄🖼️
  123. Abstract 11892026-09-01 · 20:15 CT · Arie Crown Theater
    Long-term follow-up of Lynparza 2L for HR+ breast cancer: OlympiA-647
    A. Spira, C. Saura · MD Anderson Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  124. Abstract 11712026-09-04 · 16:00 CT · Arie Crown Theater
    Long-term follow-up of Kisqali neoadjuvant for HR+ breast cancer: MONALEESA-522
    M. Krop, J. Brahmer, S. Peters · MD Anderson Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  125. Abstract 64042026-09-05 · 20:00 CT · Arie Crown Theater
    Real-world effectiveness of Opdivo vs standard of care in RCC
    M. Reck, S. Tolaney, J. Brahmer, et al. · Massachusetts General Hospital
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  126. Abstract 61232026-09-02 · 19:45 CT · S406
    KEYNOTE-320: Keytruda (pembrolizumab) 2L in RCC
    P. Schmid, T. Mok, R. Herbst · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  127. Abstract 49952026-09-04 · 16:15 CT · E450
    ASCENT-936: Trodelvy (sacituzumab govitecan) 2L in urothelial carcinoma
    G. Curigliano, M. Krop · Peter MacCallum Cancer Centre
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  128. Abstract 14942026-09-03 · 18:15 CT · Arie Crown Theater
    OlympiA-848: Lynparza (olaparib) 2L in HR+ breast cancer
    C. Saura, E. Winer, J. Brahmer, et al. · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  129. Abstract 18682026-09-03 · 13:45 CT · E450
    Real-world effectiveness of Ibrance vs standard of care in HR+ breast cancer
    C. Saura, H. Rugo, H. Borghaei, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionBreast Cancer—Metastatic📄🖼️
  130. Abstract 13112026-09-05 · 14:45 CT · Arie Crown Theater
    MONARCH-724: Verzenio (abemaciclib) 2L in HR+ breast cancer
    S. Tolaney, E. Winer, L. Paz-Ares, et al. · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  131. Abstract 11392026-09-05 · 18:00 CT · Hall B1
    PALOMA-630: Ibrance (palbociclib) 1L in HR+ breast cancer
    H. Borghaei, L. Paz-Ares, H. Rugo, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  132. Abstract 11962026-09-04 · 20:45 CT · E450
    MONARCH-745: Verzenio (abemaciclib) maintenance in HR+ breast cancer
    E. Winer, S. Peters · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
  133. Abstract 46142026-09-03 · 16:45 CT · Arie Crown Theater
    DESTINY-Breast-916: Enhertu (trastuzumab deruxtecan) neoadjuvant in gastric
    A. Spira, H. Borghaei, S. Tolaney, et al. · Stanford Cancer Institute
    Poster SessionGastrointestinal Cancer📄🖼️
  134. Abstract 95302026-09-02 · 21:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Keytruda in SCLC (the KEYNOTE-579 study)
    M.C. Garassino, M. Krop, C. Robert · Chinese University of Hong Kong
    Poster SessionLung Cancer—Small Cell📄🖼️
  135. Abstract 11742026-09-05 · 15:00 CT · Hall B1
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-21
    H. Rugo, L. Paz-Ares · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  136. Abstract 41142026-09-01 · 15:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Padcev in urothelial carcinoma (the EV-827 study)
    H. Borghaei, H. Rugo, C. Robert, et al. · Mayo Clinic
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  137. Abstract 43012026-09-01 · 21:45 CT · Hall B1
    Long-term follow-up of Trodelvy 1L for urothelial carcinoma: ASCENT-180
    M. Krop, G. Curigliano, M. Reck · Johns Hopkins Kimmel Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  138. Abstract 98372026-09-02 · 13:00 CT · E450
    Quality of life outcomes with Tagrisso in patients with NSCLC
    J. Cortes, R. Herbst · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  139. Abstract 12012026-09-05 · 21:00 CT · S100A
    MONALEESA-234: Kisqali (ribociclib) 1L in HR+ breast cancer
    A. Spira, H. Rugo, L. Paz-Ares, et al. · National Cancer Center Japan
    Poster SessionBreast Cancer—Metastatic📄🖼️
  140. Abstract 90372026-09-01 · 20:45 CT · S100A
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-761 study)
    T. Mok, F. Andre, S. Tolaney · Institut Gustave Roussy
    Poster SessionLung Cancer—Small Cell📄🖼️
  141. Abstract 41622026-09-05 · 20:15 CT · E450
    ASCENT-438: Trodelvy (sacituzumab govitecan) neoadjuvant in urothelial carcinoma
    A. Spira, C. Saura, J. Brahmer · Johns Hopkins Kimmel Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  142. Abstract 40222026-09-03 · 20:15 CT · Arie Crown Theater
    ASCENT-236: Trodelvy (sacituzumab govitecan) neoadjuvant in urothelial carcinoma
    E. Winer, S. Antonia, S. Modi · Karolinska Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  143. Abstract 92872026-09-05 · 15:30 CT · S100A
    Long-term follow-up of Imfinzi neoadjuvant for SCLC: PACIFIC-555
    S. Tolaney, C. Robert · Dana-Farber Cancer Institute
    Poster SessionLung Cancer—Small Cell📄🖼️
  144. Abstract 46112026-09-02 · 15:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Imfinzi in biliary tract (the PACIFIC-932 study)
    T. Mok, S. Modi · Princess Margaret Cancer Centre
    Poster SessionGastrointestinal Cancer📄🖼️
  145. Abstract 14912026-09-01 · 20:30 CT · Arie Crown Theater
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-844
    S. Peters, M. Krop, H. Rugo, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  146. Abstract 96362026-09-05 · 20:15 CT · S406
    Long-term follow-up of Enhertu 2L for NSCLC: DESTINY-Breast-9
    J. Brahmer, G. Curigliano, M. Reck, et al. · Dana-Farber Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  147. Abstract 10662026-09-04 · 21:00 CT · S100A
    Long-term follow-up of Lynparza 2L for HR+ breast cancer: OlympiA-773
    M. Reck, H. Borghaei, J. Brahmer · Peter MacCallum Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  148. Abstract 46382026-09-04 · 20:00 CT · Hall B1
    DESTINY-Breast-148: Enhertu (trastuzumab deruxtecan) maintenance in gastric
    G. Curigliano, C. Robert · Vall d'Hebron Institute of Oncology
    Poster SessionGastrointestinal Cancer📄🖼️
  149. Abstract 45942026-09-01 · 20:15 CT · E450
    Long-term follow-up of Padcev adjuvant for urothelial carcinoma: EV-272
    M. Krop, S. Modi, S. Tolaney · Massachusetts General Hospital
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  150. Abstract 16642026-09-05 · 13:00 CT · S100A
    MONARCH-956: Verzenio (abemaciclib) maintenance in HR+ breast cancer
    S. Tolaney, T. Mok, S. Peters · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
  151. Abstract 12732026-09-01 · 14:15 CT · Hall B1
    Long-term follow-up of Lynparza 2L for HR+ breast cancer: OlympiA-609
    E. Winer, N. Rizvi, L. Paz-Ares · Peter MacCallum Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  152. Abstract 13172026-09-03 · 19:45 CT · S406
    Long-term follow-up of Lynparza neoadjuvant for HR+ breast cancer: OlympiA-876
    R. Herbst, T. Mok · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  153. Abstract 17612026-09-02 · 13:00 CT · S100A
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-882
    E. Winer, F. Andre, N. Rizvi, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  154. Abstract 43252026-09-03 · 13:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Trodelvy in urothelial carcinoma (the ASCENT-648 study)
    S. Modi, J. Brahmer, H. Borghaei, et al. · National Cancer Center Japan
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  155. Abstract 92502026-09-05 · 19:30 CT · Arie Crown Theater
    Long-term follow-up of Keytruda neoadjuvant for NSCLC: KEYNOTE-475
    S. Tolaney, P. Schmid, T. Mok, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  156. Abstract 18312026-09-05 · 14:00 CT · Hall B1
    Real-world effectiveness of Lynparza vs standard of care in HR+ breast cancer
    J. Brahmer, E. Winer, G. Curigliano, et al. · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  157. Abstract 96702026-09-03 · 18:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Keytruda in NSCLC (the KEYNOTE-161 study)
    H. Borghaei, R. Herbst, F. Andre, et al. · Massachusetts General Hospital
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  158. Abstract 94462026-09-05 · 15:30 CT · Hall B1
    Quality of life outcomes with Imfinzi in patients with SCLC
    S. Antonia, T. Mok, H. Rugo, et al. · Stanford Cancer Institute
    Poster SessionLung Cancer—Small Cell📄🖼️
  159. Abstract 16742026-09-01 · 14:30 CT · Hall B1
    MONALEESA-375: Kisqali (ribociclib) maintenance in HR+ breast cancer
    G. Curigliano, M.C. Garassino · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  160. Abstract 91722026-09-03 · 16:00 CT · S406
    DESTINY-Breast-71: Enhertu (trastuzumab deruxtecan) 3L+ in NSCLC
    J. Brahmer, M. Krop · Chinese University of Hong Kong
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  161. Abstract 97922026-09-05 · 13:15 CT · S100A
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-846 study)
    C. Saura, E. Winer, L. Paz-Ares, et al. · Karolinska Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  162. Abstract 12932026-09-01 · 19:00 CT · Arie Crown Theater
    MONALEESA-535: Kisqali (ribociclib) maintenance in HR+ breast cancer
    M. Krop, H. Borghaei, R. Herbst, et al. · MD Anderson Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  163. Abstract 99312026-09-02 · 20:15 CT · S100A
    FLAURA-543: Tagrisso (osimertinib) neoadjuvant in NSCLC
    M. Reck, H. Borghaei, F. Andre · Massachusetts General Hospital
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  164. Abstract 45222026-09-03 · 15:00 CT · E450
    EV-875: Padcev (enfortumab vedotin) adjuvant in urothelial carcinoma
    F. Andre, H. Rugo, S. Modi, et al. · University of Chicago
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  165. Abstract 41462026-09-04 · 20:30 CT · S100A
    Long-term follow-up of Trodelvy maintenance for urothelial carcinoma: ASCENT-123
    S. Tolaney, A. Spira · Royal Marsden Hospital
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  166. Abstract 48192026-09-02 · 13:00 CT · S406
    Tecentriq plus chemotherapy in previously untreated HCC: updated analysis from IMpower-602
    S. Antonia, S. Tolaney, L. Paz-Ares, et al. · Stanford Cancer Institute
    Poster SessionGastrointestinal Cancer📄🖼️
  167. Abstract 13652026-09-01 · 16:00 CT · Arie Crown Theater
    DESTINY-Breast-62: Enhertu (trastuzumab deruxtecan) neoadjuvant in HR+ breast cancer
    F. Andre, S. Tolaney, J. Cortes · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  168. Abstract 42322026-09-04 · 14:00 CT · E450
    IMpower-556: Tecentriq (atezolizumab) 2L in HCC
    H. Rugo, C. Robert, E. Winer · Dana-Farber Cancer Institute
    Poster SessionGastrointestinal Cancer📄🖼️
  169. Abstract 45922026-09-03 · 20:45 CT · S100A
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-271
    H. Borghaei, H. Rugo, S. Peters, et al. · Chinese University of Hong Kong
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  170. Abstract 15812026-09-01 · 16:00 CT · E450
    PALOMA-799: Ibrance (palbociclib) 2L in HR+ breast cancer
    F. Andre, N. Rizvi, C. Robert, et al. · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  171. Abstract 16202026-09-04 · 21:45 CT · S100A
    Long-term follow-up of Keytruda neoadjuvant for TNBC: KEYNOTE-71
    H. Rugo, C. Saura · Chinese University of Hong Kong
    Poster SessionBreast Cancer—Metastatic📄🖼️
  172. Abstract 15782026-09-04 · 15:45 CT · Hall B1
    Long-term follow-up of Enhertu maintenance for HR+ breast cancer: DESTINY-Breast-794
    S. Modi, S. Peters, T. Mok · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  173. Abstract 18152026-09-02 · 19:45 CT · Arie Crown Theater
    Long-term follow-up of Lynparza maintenance for HR+ breast cancer: OlympiA-868
    C. Saura, A. Spira, M.C. Garassino · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  174. Abstract 61462026-09-01 · 14:30 CT · S406
    Long-term follow-up of Opdivo 3L+ for RCC: CheckMate-572
    H. Borghaei, A. Spira, M. Krop, et al. · Mayo Clinic
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  175. Abstract 43722026-09-01 · 20:45 CT · S406
    DESTINY-Breast-374: Enhertu (trastuzumab deruxtecan) neoadjuvant in gastric
    M.C. Garassino, S. Peters · Cleveland Clinic
    Poster SessionGastrointestinal Cancer📄🖼️
  176. Abstract 47012026-09-02 · 16:00 CT · S100A
    Long-term follow-up of Padcev 3L+ for urothelial carcinoma: EV-526
    S. Tolaney, H. Borghaei, S. Modi · Institut Gustave Roussy
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  177. Abstract 13552026-09-01 · 13:30 CT · E450
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-980 study)
    E. Winer, N. Rizvi · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
  178. Abstract 19862026-09-02 · 14:45 CT · S406
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-268 study)
    M.C. Garassino, R. Herbst, J. Brahmer · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  179. Abstract 93772026-09-02 · 21:45 CT · E450
    FLAURA-404: Tagrisso (osimertinib) adjuvant in NSCLC
    C. Saura, F. Andre, M. Reck, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  180. Abstract 49012026-09-04 · 20:00 CT · S406
    Imfinzi plus chemotherapy in previously untreated biliary tract: updated analysis from PACIFIC-865
    L. Paz-Ares, S. Antonia, H. Rugo, et al. · Mayo Clinic
    Poster SessionGastrointestinal Cancer📄🖼️
  181. Abstract 91902026-09-05 · 15:30 CT · Arie Crown Theater
    Long-term follow-up of Tagrisso 1L for NSCLC: FLAURA-809
    H. Rugo, M. Krop · Johns Hopkins Kimmel Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  182. Abstract 61542026-09-04 · 14:15 CT · E450
    OlympiA-606: Lynparza (olaparib) neoadjuvant in ovarian
    M.C. Garassino, H. Rugo, P. Schmid, et al. · Massachusetts General Hospital
    Poster SessionGynecologic Cancer📄🖼️
  183. Abstract 61982026-09-03 · 16:45 CT · S100A
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-22
    J. Cortes, M. Krop, E. Winer, et al. · University of Chicago
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  184. Abstract 94192026-09-05 · 18:30 CT · E450
    Real-world effectiveness of Keytruda vs standard of care in SCLC
    J. Brahmer, T. Mok, M.C. Garassino · Princess Margaret Cancer Centre
    Poster SessionLung Cancer—Small Cell📄🖼️
  185. Abstract 48152026-09-05 · 15:30 CT · E450
    EV-582: Padcev (enfortumab vedotin) neoadjuvant in urothelial carcinoma
    C. Saura, H. Rugo, H. Borghaei, et al. · Institut Gustave Roussy
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  186. Abstract 44622026-09-04 · 19:00 CT · S100A
    Long-term follow-up of Trodelvy neoadjuvant for urothelial carcinoma: ASCENT-926
    M. Krop, G. Curigliano, N. Rizvi, et al. · Dana-Farber Cancer Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  187. Abstract 13272026-09-01 · 13:00 CT · Hall B1
    ASCENT-872: Trodelvy (sacituzumab govitecan) maintenance in TNBC
    S. Peters, P. Schmid · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  188. Abstract 56842026-09-04 · 20:45 CT · Hall B1
    Long-term follow-up of Lynparza 2L for prostate: OlympiA-864
    S. Tolaney, J. Brahmer, F. Andre · Peter MacCallum Cancer Centre
    Poster SessionGenitourinary Cancer—Prostate📄🖼️
  189. Abstract 94482026-09-05 · 16:00 CT · E450
    Real-world effectiveness of Imfinzi vs standard of care in NSCLC
    P. Schmid, M. Krop · University of Chicago
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  190. Abstract 46782026-09-01 · 21:30 CT · S406
    Biomarker subgroup analysis of Padcev in urothelial carcinoma (the EV-896 study)
    J. Brahmer, J. Cortes, N. Rizvi, et al. · Chinese University of Hong Kong
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  191. Abstract 10142026-09-01 · 20:45 CT · E450
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-719 study)
    R. Herbst, A. Spira · MD Anderson Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  192. Abstract 14902026-09-01 · 19:15 CT · Hall B1
    Long-term follow-up of Trodelvy 2L for TNBC: ASCENT-980
    S. Modi, A. Spira · Chinese University of Hong Kong
    Poster SessionBreast Cancer—Metastatic📄🖼️
  193. Abstract 14472026-09-02 · 13:30 CT · Hall B1
    ASCENT-594: Trodelvy (sacituzumab govitecan) neoadjuvant in TNBC
    L. Paz-Ares, S. Antonia, E. Winer, et al. · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  194. Abstract 40572026-09-01 · 21:30 CT · E450
    Quality of life outcomes with Tecentriq in patients with HCC
    M.C. Garassino, G. Curigliano, S. Peters, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionGastrointestinal Cancer📄🖼️
  195. Abstract 91142026-09-01 · 21:45 CT · S406
    Long-term follow-up of Tagrisso maintenance for NSCLC: FLAURA-946
    H. Borghaei, S. Tolaney, C. Saura, et al. · Karolinska Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  196. Abstract 42562026-09-03 · 16:15 CT · Hall B1
    Trodelvy plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from ASCENT-69
    P. Schmid, S. Peters · Stanford Cancer Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  197. Abstract 97012026-09-02 · 19:15 CT · Arie Crown Theater
    Opdivo plus chemotherapy in previously untreated NSCLC: updated analysis from CheckMate-554
    M. Krop, S. Antonia, F. Andre · Karolinska Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  198. Abstract 44802026-09-03 · 13:45 CT · S100A
    Trodelvy plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from ASCENT-854
    J. Brahmer, S. Modi, M. Krop, et al. · Karolinska Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  199. Abstract 18242026-09-02 · 21:15 CT · S406
    MONARCH-568: Verzenio (abemaciclib) 1L in HR+ breast cancer
    J. Brahmer, M.C. Garassino · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  200. Abstract 14742026-09-05 · 14:00 CT · S100A
    MONARCH-875: Verzenio (abemaciclib) maintenance in HR+ breast cancer
    E. Winer, P. Schmid, J. Cortes · Peter MacCallum Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.